Organisation paid for research Program year 2025 Source: CMS Open Payments

Central Michigan University

Neither a doctor nor a teaching hospital

Research payments

$764,284

161 payments

Through program year 2025, Central Michigan University is reported as receiving $764,284 in research payments, across 161 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $207,703 50
2024 Research $210,876 64
2023 Research $211,391 34
2022 Research $93,200 9
2021 Research $41,115 4

Breakdown

Who paid Research payments · program years 2021–2025
  1. Agios Pharmaceuticals, Inc. $283,832 57 payments
  2. Bausch Health US, LLC $70,026 14 payments
  3. Eli Lilly and Company $56,559 4 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $43,540 11 payments
  5. Marinus Pharmaceuticals, Inc. $40,806 3 payments
  6. BioMarin Pharmaceutical Inc. $40,705 8 payments
  7. Global Blood Therapeutics, Inc. $33,668 6 payments
  8. Sanofi US Services Inc. $28,993 9 payments
  9. Pfizer Inc. $28,452 4 payments
  10. Hoffmann-La Roche Limited $28,011 8 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease $158,107 20 payments
  2. A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell Disease $70,026 14 payments
  3. Ag348-C-023 $62,967 20 payments
  4. Ag348-C-018 $42,706 15 payments
  5. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $28,829 1 payment
  6. Phase I PK PD Safety and Efficacy Study of Open Label Tocilizumab in Children With Covid 19 $28,011 8 payments
  7. An Open-Label, Phase 3 Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohns Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy $27,469 9 payments
  8. BMN 270-401 $23,965 7 payments
  9. Pompe Disease Registry $22,445 5 payments
  10. A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (Ia) Or Invasive Mucormycosis (Im) in Pediatric Subjects $20,166 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record